MDGL Q3 2023 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$99M

Net Income

-$99M

EPS (Diluted)

$-5.34

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$85M

Free Cash Flow

-$85M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$238M

Total Liabilities

$216M

Stockholders' Equity

$22M

Cash & Equivalents

$62M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$99M	-$80M	-22.5%
Net Income	-$99M	-$81M	-21.6%